The polymorphism of paraoxonase and its effects in physiological and pathological processes;Polimorfizm paraoksonazy a procesy fizjologiczne i patologiczne

Advances in Clinical and Experimental Medicine

Volumn 15, Issue 6, 2006, Pages 1073-1078

  Zielaskowska, Jowita ^a,b   Olszewska Słonina, Dorota ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Oxidation of LDL; Paraoxonase

Indexed keywords

ALCOHOL; ARGININE; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; HYDROPEROXIDE DERIVATIVE; ISOPROTEIN; LEUCINE; LOW DENSITY LIPOPROTEIN; METHIONINE; NICOTINE; ORGANOPHOSPHATE; OXYGEN; PARAOXON; SARIN;

DIET; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENE CONTROL; GENETIC POLYMORPHISM; HUMAN; ISCHEMIC HEART DISEASE; LIPID OXIDATION; METABOLIC DISORDER; MOLECULAR MECHANICS; PATHOPHYSIOLOGY; PROTEIN FAMILY; PROTEIN HYDROLYSIS; REVIEW;

EID: 33846685210     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983, 35, 1126-38.
2. Furlong CE, Richter RJ, Chapline C, Crabb JW: Purification of rabbit and human serum paraoxonase. Biochemistry 1991, 30, 10133-10140.
3. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996, 7, 69-76.
4. La Du BN, Adkins S, Kuo CL, Lipsig D: Studies on human serum paraoxonase/ arylesterase. Chem Biol Interact 1993, 87, 25-34.
5. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001, 21, 1451-1457.
6. Hegele RA, Brunt JH, Connelly PW: A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995, 15, 89-95.
7. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL: Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999, 26, 892-904.
8. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonky O, Meged R, Dvir H, Ravelli R, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS: Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004, 11, 5, 412-419.
9. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN: The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33, 498-507.
10. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993, 3, 73-76.
11. Kuo C-L, La Du BN: Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metabol Diopos 1998, 26, 653-660.
12. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogui J, Hsu C, Dunlop C, La Du BN: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R Arterioscler Thromb Vasc Biol 1998, 18, 1617-1624.
13. Gotto AM Jr: High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002, 144, S33-42.
14. Adkins S, Gan KN, Mody M, La Du BN: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993, 52. 598-608.
15. La Du BN: Structural and functional diversity of paraoxonases. Nat Med1996, 2, 1186-1187.
16. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998, 423, 57-60.
17. Agachan B, Yilmaz H, Isbir T, Akoglu E: Paraoxonase 192 polymorphism and its relationship to serum lipids in Turkish renal transplant recipients. Transplant Proc 2004, 36, 1385-1386.
18. Durrington PN, Mackness B, Mackness MI: Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21, 473-480.
19. La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA: Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos 2001, 29, 566-569.
20. Sanghera DK, Saha N, Kamboh MI: The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 1998, 136, 217-223.
21. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W: Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Natl Acad Sci USA 1998, 95 (13), 7614-7619.
22. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI: Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 2001, 354, 1-7.
23. Nguyen SD, Sok DE: Effect of 3,4-dihydroxyphenylalanine on Cu(2+)-induced inactivation of HDL-associated paraoxonase and oxidation of HDL; inactivation of paraoxonase activity independent of HDL lipid oxidation. Free Radic Res 2004, 38: 969-976.
24. Leviev I, James RW: Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000, 20, 516-521.
25. Sanghera DK, Saha N, Aston CE, Kamboh MI: Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997, 17, 1067-1073.
26. Salonen JT, Malin R, Tuomainen TP, Nyyssonen K, Lakka TA, Lehtimaki T: Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study. BMJ 1999, 319, 487-489.
27. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE: Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002, 22, 1329-1333.
28. Rantala M, Silaste ML, Tuominen A, Kaikkonen J, Salonen JT, Alfthan G: Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 2002, 132, 3012-3017.
29. Rao MN, Marmillot P, Gong M, Palmer DA, Seeff LB, Strader DB: Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 2003, 52, 1287-1294.
30. Marchesani M, Hakkarainen A, Tuomainen TP, Kaikkonen J, Pukkala E, Uimari P, Seppala, E, Matikainen M, Kallioniemi O, Schleutker J, Lehtimaki T, Salonen J: New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst 2003, 95, 812-818.
31. Berry R, Schaid DJ, Smith JR French AJ, Schroeder JJ, McDonnell SK, Peterson BJ, Wang ZY, Carpten JD, Roberts SG, Tester DJ, Blute ML, Trent JM, Thibodeau SN: Linkage analyses at the chromosome 1 loci lq24-25 (HPCl), lq42.2-43 (PCAP), and lp36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 2000, 66, 539-546.
32. Berthon P, Valeri A, Cohen-Akenine A: Predisposing gene for early-onset prostate cancer, localized on chromosome lq42.2-43. Am J Hum Genet 1998, 62, 1416-1424.
33. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA: Evidence for a rare prostate cancer - susceptibility locus at chromosome lp36. Am J Hum Genet 1999, 64, 776-787.
34. Rebbeck TR: Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000, 67, 1014-1019.
35. Smith JR, Freije D, Carpten JD Gronberg H, Xu J, Isacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Daniels J, Baailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996, 274, 1371-1374.
36. Xu J, Meyers D, Freije D: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998, 20, 175-179.
37. Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L: Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48, 261-268.